Natixis Advisors LLC Boosts Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Natixis Advisors LLC raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 56.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 18,184 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,545 shares during the period. Natixis Advisors LLC’s holdings in ANI Pharmaceuticals were worth $1,085,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Sequoia Financial Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $600,000. Susquehanna Fundamental Investments LLC acquired a new stake in ANI Pharmaceuticals during the second quarter worth approximately $228,000. Boston Partners purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth approximately $606,000. Renaissance Technologies LLC raised its holdings in ANI Pharmaceuticals by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company’s stock valued at $9,985,000 after acquiring an additional 20,900 shares during the last quarter. Finally, Mizuho Markets Americas LLC purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth $11,670,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Raymond James increased their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. Finally, Truist Financial increased their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $77.33.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $57.86 on Wednesday. The company has a 50-day moving average of $58.36 and a two-hundred day moving average of $60.83. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -105.29 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 EPS. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.